The increased expression of the ligands for PD-1 and CLTA-4 in human pituitary tumors suggests that immunotherapeutic antibodies such as ipilimumab and nivolumab may be able to directly target clinically aggressive pituitary tumors resistant to therapy. Here, PDCD1 is linked to pituitary tumor.